MK-8189 PDE10A Inhibitor Failed Schizophrenia Phase 2b PANSS Endpoint
TL;DR: A 2026 randomized phase 2b trial in Journal of Clinical Psychopharmacology found that the PDE10A inhibitor MK-8189 did not improve Positive and Negative Syndrome Scale (PANSS) schizophrenia symptom scores more than placebo after 6 weeks, while risperido…
Read article